Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-26
DOI
10.1186/s13045-021-01076-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML
- (2019) Le Xuan Truong Nguyen et al. JOURNAL OF CELLULAR PHYSIOLOGY
- 8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia
- (2019) Ralf Buettner et al. JOURNAL OF CELLULAR PHYSIOLOGY
- New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise
- (2019) Stephan R. Bohl et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia
- (2019) Nicolas Chapuis et al. Frontiers in Oncology
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- TP53INP2 regulates adiposity by activating β-catenin through autophagy-dependent sequestration of GSK3β
- (2018) Montserrat Romero et al. NATURE CELL BIOLOGY
- FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia
- (2018) Kelly J. Norsworthy et al. ONCOLOGIST
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
- (2018) Courtney L. Jones et al. CANCER CELL
- FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
- (2018) Aviva C Krauss et al. CLINICAL CANCER RESEARCH
- Cholesterol and fatty acids regulate cysteine ubiquitylation of ACAT2 through competitive oxidation
- (2017) Yong-Jian Wang et al. NATURE CELL BIOLOGY
- 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition
- (2015) Alper Y. Kearney et al. PLoS One
- ATP directed agent, 8-chloro-adenosine, induces AMP activated protein kinase activity, leading to autophagic cell death in breast cancer cells
- (2014) Christine M Stellrecht et al. Journal of Hematology & Oncology
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
- (2013) Eleni D. Lagadinou et al. Cell Stem Cell
- Acute myelogenous leukemia stem cells: From Bench to Bedside
- (2012) J. Felipe Rico et al. CANCER LETTERS
- 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma
- (2010) J. B. Dennison et al. BLOOD
- Inhibition of ATP synthase by chlorinated adenosine analogue
- (2009) Lisa S. Chen et al. BIOCHEMICAL PHARMACOLOGY
- A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels
- (2009) Christine M. Stellrecht et al. BREAST CANCER RESEARCH AND TREATMENT
- Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis
- (2009) Jennifer B. Dennison et al. BRITISH JOURNAL OF HAEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started